Physician profile
Glenn Waldman
NPI 1881665586
$143,739.52
in general payments reported to CMS, 2019-2025
19 companies · $1,195 in 2025
The $1,195 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52K · 2020: $16K · 2021: $19K · 2022: $39K · 2023: $6,664 · 2024: $9,559 · 2025: $1,195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Food and Beverage: $3,667 · Travel and Lodging: $1,783 · Education: $67.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,900.00 |
| Food and Beverage | $3,667.15 |
| Travel and Lodging | $1,782.99 |
| Education | $67.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $139,444.35 | 2019-2025 | Xpress Loprofile, Latera, Xpress Ent Dilation System |
| Glaxosmithkline, LLC. | $1,380.66 | 2021-2025 | Nucala |
| Genzyme Corporation | $931.65 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $723.97 | 2019-2025 | Dupixent |
| Aerin Medical INC. | $402.51 | 2023-2025 | |
| Galderma Laboratories, L.P. | $182.71 | 2019-2021 | |
| Olympus America INC. | $150.00 | 2022 | |
| Amniox Medical, INC. | $110.54 | 2020 | |
| Sanofi-Aventis U.S. LLC | $67.99 | 2024 | |
| Smith+Nephew, INC. | $63.00 | 2019 | |
| Medtronic, INC. | $57.43 | 2022 | |
| Neurent Medical Limited | $55.30 | 2023-2025 | Neuromark Radiofrequency Console, Neuromark Device, Neuromark System |
| Biotissue Holdings INC. | $36.15 | 2021 | |
| Phathom Pharmaceuticals, INC. | $27.95 | 2025 | Voquezna |
| Intersect Ent, INC. | $26.46 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $25.54 | 2025 | Tezspire |
| Pacira Pharmaceuticals Incorporated | $20.06 | 2021 | |
| Allergan, INC. | $19.32 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.93 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Waldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.